Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway

Ma,Yu-Chao; Li,Cui; Gao,Feng; Xu,Yan; Jiang,Zhi-Bin; Liu,Jian-Xin; Jin,Long-Yu

doi:10.3892/or.2013.2933

Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway

Authors:
- Yu-Chao Ma
- Cui Li
- Feng Gao
- Yan Xu
- Zhi-Bin Jiang
- Jian-Xin Liu
- Long-Yu Jin
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, P.R. China, Key Laboratory of Cancer Proteomics of the Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha 410008, P.R. China, Department of Ultrasound, The Third Xiangya Hospital, Central South University, Changsha 410013, P.R. China
Published online on: December 19, 2013 https://doi.org/10.3892/or.2013.2933
Pages: 1343-1349

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epigallocatechin gallate (EGCG), the major biologically active compound in green tea, is a well-known chemoprevention agent. Although several reports have shown that EGCG exerts its anticancer activity by targeting specific cell signaling pathways, the underlying molecular mechanism(s) are only partially understood. In the present study, we report that EGCG had a profound antiproliferative effect on human lung cancer cells. EGCG inhibited anchorage-independent growth and induced cell cycle G0/G1 phase arrest. The mechanism underlying EGCG antitumor potency was mainly dependent on suppression of the EGFR signaling pathway. Short-term EGCG exposure substantially decreased EGF-induced EGFR, AKT and ERK1/2 activation. Moreover, long-term EGCG treatment not only inhibited total and membranous EGFR expression, but also markedly attenuated EGFR nuclear localization and expression of the downstream target gene cyclin D1, indicating that EGCG treatment suppressed EGFR transactivation. Additionally, knockdown of EGFR in lung cancer cells decreased their sensitivity to EGCG. Thus, inhibition of the EGFR signaling pathway may partly contribute to the anticancer activity of EGCG.

View Figures

View References

1	Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH and Dou QP: Recent advances on tea polyphenols. Front Biosci (Elite Ed). 4:111–131. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jin L, Li C, Xu Y, Wang L, Liu J, Wang D, et al: Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep. 29:1983–1990. 2013.PubMed/NCBI
3	Park JS, Khoi PN, Joo YE, Lee YH, Lang SA, Stoeltzing O, et al: EGCG inhibits recepteur d’origine nantais expression by suppressing Egr-1 in gastric cancer cells. Int J Oncol. 42:1120–1126. 2013.
4	Yiannakopoulou EC: Effect of green tea catechins on breast carcinogenesis: a systematic review of in-vitro and in-vivo experimental studies. Eur J Cancer Prev. Aug 9–2013.(Epub ahead of print).
5	Hagen RM, Chedea VS, Mintoff CP, Bowler E, Morse HR and Ladomery MR: Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int J Oncol. 43:194–200. 2013.PubMed/NCBI
6	Kim SO and Kim MR: (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. Int J Oncol. 42:349–358. 2013.
7	Chen H, Landen CN, Li Y, Alvarez RD and Tollefsbol TO: Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol. 2013:8729572013. View Article : Google Scholar
8	Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, et al: Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett. 42:60–69. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ogawa K, Hara T, Shimizu M, Nagano J, Ohno T, Hoshi M, et al: (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. Oncol Lett. 4:546–550. 2012.PubMed/NCBI
10	Chiou YS, Sang S, Cheng KH, Ho CT, Wang YJ and Pan MH: Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34⁺ skin stem cells and skin tumors. Carcinogenesis. 34:1315–1322. 2013. View Article : Google Scholar : PubMed/NCBI
11	Shimizu M, Adachi S, Masuda M, Kozawa O and Moriwaki H: Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res. 55:832–843. 2011. View Article : Google Scholar : PubMed/NCBI
12	Fujiki H and Suganuma M: Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett. 324:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
13	Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
14	Singh BN, Shankar S and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 82:1807–1821. 2011. View Article : Google Scholar : PubMed/NCBI
15	Han W and Lo HW: Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 318:124–134. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tebbutt N, Pedersen MW and Johns TG: Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 13:663–673. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kolch W and Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 10:618–629. 2010. View Article : Google Scholar : PubMed/NCBI
18	Avraham R and Yarden Y: Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 12:104–117. 2011. View Article : Google Scholar : PubMed/NCBI
19	Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, et al: Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology. 13:15–20. 1991. View Article : Google Scholar : PubMed/NCBI
20	Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 7:575–589. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y and Hung MC: Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog. 45:10–17. 2006. View Article : Google Scholar : PubMed/NCBI
23	Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML, et al: Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res. 36:4337–4351. 2008. View Article : Google Scholar : PubMed/NCBI
24	Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al: Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 280:31182–31189. 2005. View Article : Google Scholar : PubMed/NCBI
25	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
26	Katlic MR, Facktor MA, Berry SA, McKinley KE, Bothe A Jr and Steele GD Jr: ProvenCare lung cancer: a multi-institutional improvement collaborative. CA Cancer J Clin. 61:382–396. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
28	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
29	Herbst RS, Fukuoka M and Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer. 4:956–965. 2004. View Article : Google Scholar : PubMed/NCBI
30	Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
31	Tao Y, Song X, Deng X, Xie D, Lee LM, Liu Y, et al: Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res. 303:240–251. 2005. View Article : Google Scholar
32	Shi Y, Tao Y, Jiang Y, Xu Y, Yan B, Chen X, et al: Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1. Carcinogenesis. 33:1468–1478. 2012. View Article : Google Scholar
33	Sato M, Shames DS, Gazdar AF and Minna JD: A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2:327–343. 2007. View Article : Google Scholar : PubMed/NCBI
34	Shimizu M, Shirakami Y and Moriwaki H: Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci. 9:1034–1049. 2008. View Article : Google Scholar : PubMed/NCBI
35	Masuda M, Suzui M and Weinstein IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 7:4220–4229. 2001.PubMed/NCBI
36	Hou Z, Sang S, You H, Lee MJ, Hong J, Chin KV, et al: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res. 65:8049–8056. 2005.
37	Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, et al: The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res. 67:6493–6501. 2007. View Article : Google Scholar : PubMed/NCBI
38	Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, et al: The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res. 15:4885–4894. 2009. View Article : Google Scholar : PubMed/NCBI
39	Adachi S, Shimizu M, Shirakami Y, Yamauchi J, Natsume H, Matsushima-Nishiwaki R, et al: (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis. 30:1544–1552. 2009. View Article : Google Scholar : PubMed/NCBI
40	Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 7(Suppl 4): S31–S39. 2002. View Article : Google Scholar : PubMed/NCBI